Royalty Pharma PLC (NASDAQ:RPRX) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET
Company Participants
George Grofik - SVP & Head, IR & Communications
Pablo Legorreta - Founder, Chairman & CEO
Christopher Hite - Vice Chairman & EVP
Terrance Coyne - EVP & CFO
Marshall Urist - EVP & Head, Research & Investments
Conference Call Participants
Christopher Schott - JPMorgan Chase & Co.
Stephen Scala - TD Cowen
Andrew Baum - Citigroup
Michael DiFiore - Evercore ISI
Chris Shibutani - Goldman Sachs Group
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma Third Quarter 2023 Earnings Conference Call. I would like now to turn the conference over to George Grofik, Senior Vice President, Head of Investor Relations and Communications. Please go ahead.
George Grofik
Good morning, and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma's Third Quarter 2023 results. You can find the press release with our earnings results and slides of this call on the Investors page of our website at royaltypharma.com.
Moving to Slide 3. I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from these statements. I refer you to our 10-K on file with the SEC for a description of these risks. All forward-looking statements are based on information currently available to Royalty Pharma and we assume no obligation to update any such forward-looking statements.
Non-GAAP financial measures will be used to help you understand our financial performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release available on our website. And with that, please advance to Slide 4. Our speakers on the call today are Pablo Legorreta, Founder and Chief Executive Officer; Chris Hite, EVP, Vice Chairman; Marshall Urist, EVP, Head of Research and Investments; and Terry Coyne, EVP, Chief Financial Officer.
Pablo will discuss key highlights. Chris will then provide an update on the PTC partnership, after which Marshall will discuss other portfolio updates. Next, Terry will review the financials and following concluding remarks from Pablo, we will hold the Q&A session. And with that, I'd like to turn the call over to Pablo.
Pablo Legorreta
Thank you, George, and welcome to everyone on the call. I am delighted to report another successful quarter of execution against our strategy as a leading funder of Innovation and Life Sciences.